Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
$1,318.00
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 468,100 incident cases of pancreatic cancer worldwide, and expects that number to increase to 486,300 incident cases by 2028.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase (PARP), dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor (EGFR). These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral or intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase II trial results for motixafortide; topline Phase III trial results for pamrevlumab and Onivyde; and an expected patent expiration for Abraxane.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 1.5%, and the average probability a drug advances from Phase III is 11.8%. Drugs, on average, take 10.5 years from Phase I to approval, compared to 9.8 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 100 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for pancreatic cancer, followed by Roche.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Surgery
9 Ablation or embolization
10 Radiation therapy
10 Chemotherapy
10 Targeted therapy
11 Immunotherapy
11 Drugs used specifically for the treatment of PNETs
12 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
35 RECENT EVENTS AND ANALYST OPINION
35 Zejula for Pancreatic Cancer (June 4, 2022)
36 Nimotuzumab for Pancreatic Cancer (June 3, 2022)
38 Anktiva for Pancreatic Cancer (January 18, 2022)
40 CPI-613 for Pancreatic Cancer (October 28, 2021)
42 ERY-ASP for Pancreatic Cancer (October 25, 2021)
44 Relacorilant for Pancreatic Cancer (June 22, 2021)
45 GV1001 for Pancreatic Cancer (June 6, 2021)
47 KEY UPCOMING EVENTS
48 PROBABILITY OF SUCCESS
49 LICENSING AND ASSET ACQUISITION DEALS
49 Gilead Gets 5T4-Targeted NK Cell Therapy Candidate From Dragonfly
49 Merged Cend/Caladrius To Focus First On Pancreatic Cancer
49 Redx, Garvan Institute Scientists Work To Improve Survival In Fibrotic Cancer
50 AstraZeneca Gets Bispecific Antibody From China’s Harbour Biomed
50 Qualigen Licenses UCL Candidate For Pancreatic Cancer
50 TriSalus Announces Collaboration With University Of Colorado
51 Synthetic Biologics To Acquire Immunotherapy Firm VCN
51 Gilead Opts In On Multiple Arcus IO Candidates, Setting Up Combo Therapy Plans
51 China CSPC Subsidiary Out-Licenses Oncology Candidate To Flame Biosciences
52 Chinese Cell Developers To Jointly Develop Solid Tumor Therapies
53 REVENUE OPPORTUNITY
56 CLINICAL TRIAL LANDSCAPE
57 Sponsors by status
58 Sponsors by phase
59 Recent events
63 BIBLIOGRAPHY
64 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of pancreatic cancer, 2019–28
18 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
18 Figure 3: Pipeline drugs for pancreatic cancer, by company
19 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
19 Figure 5: Pipeline drugs for pancreatic cancer, by classification
36 Figure 6: Zejula for Pancreatic Cancer (June 4, 2022): Phase Ib/II – Parpvax (w/Nivolumab + Ipilimumab)
38 Figure 7: Nimotuzumab for Pancreatic Cancer (June 3, 2022): Phase III – China
40 Figure 8: Anktiva for Pancreatic Cancer (January 18, 2022): Phase II – QUILT-88
42 Figure 9: CPI-613 for Pancreatic Cancer (October 28, 2021): Phase III – AVENGER 500 (w/mFolfirinox)
45 Figure 10: Relacorilant for Pancreatic Cancer (June 22, 2021): Phase III – RELIANT (w/Nab-Paclitaxel)
47 Figure 11: Key upcoming events in pancreatic cancer
48 Figure 12: Probability of success in the pancreatic cancer pipeline
56 Figure 13: Clinical trials in pancreatic cancer
56 Figure 14: Top 10 drugs for clinical trials in pancreatic cancer
57 Figure 15: Top 10 companies for clinical trials in pancreatic cancer
57 Figure 16: Trial locations in pancreatic cancer
58 Figure 17: Pancreatic cancer trials status
59 Figure 18: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of pancreatic cancer, 2019–28
16 Table 2: Marketed drugs for pancreatic cancer
21 Table 3: Pipeline drugs for pancreatic cancer in the US
35 Table 4: Zejula for Pancreatic Cancer (June 4, 2022)
37 Table 5: Nimotuzumab for Pancreatic Cancer (June 3, 2022)
38 Table 6: Anktiva for Pancreatic Cancer (January 18, 2022)
41 Table 7: CPI-613 for Pancreatic Cancer (October 28, 2021)
43 Table 8: ERY-ASP for Pancreatic Cancer (October 25, 2021)
44 Table 9: Relacorilant for Pancreatic Cancer (June 22, 2021)
46 Table 10: GV1001 for Pancreatic Cancer (June 6, 2021)
54 Table 11: Historical global sales, by drug ($m), 2017–21
55 Table 12: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Norovirus 
Sign up to the